Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450960 | 0.86 | SLC6A2 (0.56) | ESR1ESR2SLC6A2SLC7A5TAAR1 | |
| SCHEMBL2148366 | 0.85 | SLC6A2 (0.49) | ESR1ESR2SLC6A2SLC7A5TAAR1 | |
| SCHEMBL19369770 | 0.83 | SLC6A2 (0.46) | SLC6A2 | |
| SCHEMBL8919717 | 0.82 | CYP1A2 (0.50) | SLC7A5TAAR1 | |
| SCHEMBL11308492 | 0.82 | ESR1 (0.50) | ESR1ESR2SLC6A2SLC7A5TAAR1 | |
| SCHEMBL109575 | 0.82 | CYP1A2 (0.50) | SLC7A5TAAR1 | |
| SCHEMBL8380411 | 0.82 | CYP1A2 (0.50) | SLC7A5TAAR1 | |
| SCHEMBL107420 | 0.81 | TAAR1 (0.48) | ESR1ESR2SLC6A2SLC7A5TAAR1 | |
| SCHEMBL106905 | 0.81 | TAAR1 (0.52) | ESR1ESR2SLC6A2SLC7A5TAAR1 | |
| SCHEMBL16431461 | 0.80 | FNTA (0.59) | SLC6A2SLC7A5CA2CAMK2AFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295678-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2023-09-21 | — | — | US | disclosed |
| EP-4098750-A1 | RAPID PRETREATMENT | Sweetwater Energy, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3230463-B1 | RAPID PRETREATMENT | SWEETWATER ENERGY INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20100086981-A1 | COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS | QTEROS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20090203089-A1 | ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF | BIO ARCHITECTURE LAB, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009097346-A2 | ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF | BIO ARCHITECTURE LAB, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | ESR1 3581/4885ESR2 3683/4885SLC6A2 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.